Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis.
Haematology Unit and BMT, 'San Giuseppe Moscati' Hospital, Taranto, Italy.
C
C
Minoia
Haematology Unit and BMT, 'San Giuseppe Moscati' Hospital, Taranto, Italy.
G
G
Pisapia
Haematology Unit and BMT, 'San Giuseppe Moscati' Hospital, Taranto, Italy.
G
G
Palazzo
Haematology Unit and BMT, 'San Giuseppe Moscati' Hospital, Taranto, Italy.
C
C
Ingrosso
Haematology Unit and BMT, 'San Giuseppe Moscati' Hospital, Taranto, Italy.
M
M
Buonanno
Haematology Unit and BMT, 'San Giuseppe Moscati' Hospital, Taranto, Italy.
C
C
Spinosa
Haematology Unit and BMT, 'San Giuseppe Moscati' Hospital, Taranto, Italy.
A
A
Prudenzano
Haematology Unit and BMT, 'San Giuseppe Moscati' Hospital, Taranto, Italy.
G
G
Pricolo
Haematology Unit and BMT, 'San Giuseppe Moscati' Hospital, Taranto, Italy.
P
P
Mazza
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069286:Bortezomib / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000494:pharmacology; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy / Q000628:therapy*; D011092:Polyethylene Glycols; D061988:Proteasome Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000494:pharmacology; D012074:Remission Induction; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000627:therapeutic use*; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D061988:Proteasome Inhibitors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D013792:Thalidomide; D000069286:Bortezomib; D003520:Cyclophosphamide; D000069585:Filgrastim